Johnson & Johnson (JNJ) reported mixed se꧋cond-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales.

Sales of the company's pharmaceuticals and medical devices rose just over 4% from the same time last year to $22.45 billion, better than the $22.38 billion analysts had expected, according to consensus estimates compiled by Visible Alpha. However, profits fell short of estimates due to various one-time costs like legal fees and 澳洲幸运5官方开奖结果体彩网:asset amortization costs.

Johnson & Johnson reported 🐎$4.69 billion in net income, short of the $5.66 billion analysts had expected. After accounting for the one-time expenses, however, the company posted $6.84 billion in adjusted net income, or $2.82 per share, better than the $6.59 billion and $2.71 per share anal😼ysts had anticipated.

JNJ Lifts Full-Year Sales Guidance But Lowers Profit Proဣjections

The company also shifted its full-year guidance from the last time it 澳洲幸运5官方开奖结果体彩网:updated the projections to account for the financial 澳洲幸运5官方开奖结果体彩网:impact of recent acquisitions, raising its expectations ওfor sales while also projecting lower profits than it had previo🐲usly.

For the full fiscal year, Johnson & Johnson projects operational sales from $89.2 billion to $89.6 billion, above the previous range of $88.7 billion to $89.1 billion guided in April. However, the company also lowered projections for adjusted 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) to a range of $9.97 𝕴to $10.07 from $10.57 to $10.72.

Analysts currently project sales of $88.58 billion and adjusted EPS of $10.42 for the full year, accordiꩲng to estimates compiled by Visible Alpha.

Shar🍃ꦕes rose 2% as markets opened Wednesday to $154.24 but are slightly negative for 2024.